# Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function

> **NCT04059783** · — · COMPLETED · sponsor: **Bayer** · enrollment: 272 (actual)

## Conditions studied

- Functional Gastrointestinal Disorders

## Interventions

- **DRUG:** STW5 (Iberogast®, BAY98-7411)

## Key facts

- **NCT ID:** NCT04059783
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-17
- **Primary completion:** 2010-04-27
- **Final completion:** 2011-02-20
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04059783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04059783, "Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04059783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*